EDAP TMSS. A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally.
The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services.
In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes.
Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services.
The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents.
The company serves academic, public, and private hospitals, as well as clinics.
The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer.
EDAP TMSS. A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | -0.24 Decreased by -14.29% | -0.21 Decreased by -14.29% |
| Mar 25, 26 | -0.25 Decreased by -360.11% | -0.16 Decreased by -62.36% |
| Nov 6, 25 | -0.15 Increased by +16.67% | -0.26 Increased by +42.31% |
| Aug 28, 25 | -0.17 Increased by +1.86% | -0.16 Decreased by -6.16% |
| May 15, 25 | -0.21 Decreased by -57.42% | -0.17 Decreased by -23.53% |
| Mar 27, 25 | -0.06 Increased by +63.07% | - |
| Nov 7, 24 | -0.18 Decreased by -50.00% | -0.17 Decreased by -5.88% |
| Aug 28, 24 | -0.18 Decreased by -26.71% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 17.88 M Increased by +25.28% | -9.12 M Decreased by -22.44% | Decreased by -50.99% Increased by +2.27% |
| Dec 31, 25 | 21.86 M Increased by +0.88% | -9.45 M Decreased by -356.61% | Decreased by -43.22% Decreased by -352.63% |
| Sep 30, 25 | 16.22 M Decreased by -4.59% | -5.86 M Increased by +11.24% | Decreased by -36.13% Increased by +6.97% |
| Jun 30, 25 | 18.18 M Increased by +12.38% | -6.35 M Decreased by -28.64% | Decreased by -34.91% Decreased by -14.47% |
| Mar 31, 25 | 14.27 M Decreased by -32.33% | -7.45 M Decreased by -37.31% | Decreased by -52.18% Decreased by -102.92% |
| Dec 31, 24 | 21.67 M Increased by +69.74% | -2.07 M Increased by +51.79% | Decreased by -9.55% Increased by +71.60% |
| Jun 30, 24 | 17.00 M Increased by +9.40% | -6.60 M Decreased by -29.11% | Decreased by -38.83% Decreased by -18.02% |
| Mar 31, 24 | 16.18 M Increased by +1.93% | -4.93 M Increased by +38.61% | Decreased by -30.49% Increased by +39.77% |